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25 generic visual function instrument. RESULTS: Mean age 76.8
years: 55.8% women. All had wet age-related MD (often pro-
gressing rapidly to severe visual impairment). Strong correlations
between the 22 items (r > 0.50) and factor loadings >0.49 on a
forced one-factor analysis supported use of an overall weighted
impact score. Four subscales were indicated (Cronbach’s alpha
>0.7) measuring: essential tasks, family/social life, activities/capa-
bilities, and embarrassment. Patients with BE VA < 5/10 and WE
VA < 1/10 produced signiﬁcantly worse scores than those with
BE VA >= 5/10 and WE VA >= 1/10 (MacDQoL p < 0.0001; NEI-
VFQ-25 p < 0.0001; global scores). MacDQoL score variation
coefﬁcients were lower (better) than those of NEI-VFQ-25. CON-
CLUSIONS: The analysis conﬁrmed the metric properties of 
the MacDQoL.. The MacDQoL is associated with VA though, 
as expected, not as closely as the NEI-VFQ25 visual function
measure, but offers a broader individualised measure of the
impact of MD on QoL.
PEY25
HEALTH-RELATED QUALITY-OF-LIFE AND UTILITY IN DUTCH
GLAUCOMA PATIENTS
Van Gestel A, Schouten JS,Webers CA, Beckers HJ, Schrooten MA,
Severens JL, Hendrikse F
Academic Hospital Maastricht, Maastricht,The Netherlands
OBJECTIVES: To quantify health-related quality-of-life and
utility in patients with ocular hypertension (OH) and primary
open-angle glaucoma (POAG). METHODS: A cross-sectional
survey was performed in 481 OH and POAG patients. Patients
were invited to complete a questionnaire at home. The ques-
tionnaire contained the EQ-5D, the Visual Functioning Ques-
tionnaire (VFQ-25, range 0–100 (best)) and the Glaucoma
Quality-of-Life questionnaire (GQL-15, range 0–75 (worst)).
Patients were also asked to report on demographics, treatment
history, treatment side-effects, and co-morbidities. Medical
records were consulted for clinical parameters of disease sever-
ity, such as optic nerve head excavation and visual ﬁeld loss.
RESULTS: Data-collection was ongoing at the time of writing.
The preliminary response rate is 79%. Here we report the results
of the ﬁrst 269 patients (56%) that participated. Mean age was
71.2 ± 10.4 years, 51% was male, and 91% was currently using
glaucoma medication. Trabeculectomy was self-reported in
13.8% of the patients. VFQ-25 score was 85.2 ± 14.9 in OH
patients (n = 110), 81.4 ± 15.5 in medically treated POAG
patients (n = 132) and 63.4 ± 23.4 in POAG patients with a
history of trabeculectomy (n = 27) (p < 0.001, unequal variance).
GQL-15 score was 21.8 ± 9.7, 23.6 ± 11.1 and 34.8 ± 13.4 in
these groups respectively (p < 0.001, unequal variance). EQ-5D
utility from the Dutch value set was 0.88 ± 0.18, EQ-5D VAS
was 75.9 ± 14.5; these values did not differ between groups. Pre-
liminary analyses with visual ﬁeld loss (Mean Deviation, n = 209)
in the better eye indicated no correlation with EQ-5D utility
(Spearman’s rho r = 0.1, ns) or EQ-5D VAS (r = 0.08, ns), and
weak correlations with VFQ-25 (r = 0.24, p < 0.001), and GQL-
15 (r = −0.23, p < 0.001). CONCLUSIONS: These preliminary
results indicate that vision-related quality-of-life is lower in more
severe glaucoma. Further research of the relationship between
disease severity and quality-of-life is currently being undertaken.
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VISION BENEFIT FROM MULTI-FOCAL INTRAOCULAR LENS
(IOL) AFTER CATARACT SURGERY ESTIMATED BY PRINCIPAL
COMPONENTS ANALYSIS
Berdeaux G1,Viala M2,Arnould B2
1Alcon France, Rueil-Malmaison, France, 2Mapi Values France, Lyon,
France
OBJECTIVE: Restoration of near and far vision function
without recourse to spectacles remains a major goal of cataract
surgery. ReSTOR®, a new multi-focal IOL, addresses this issue
by improving both near and far vision without spectacles. The
present analysis attempts to quantify the vision beneﬁts experi-
enced by patients. METHODS: Data from two clinical trials con-
ducted in Europe and the United States, evaluating the safety and
efﬁcacy of ReSTOR® compared to a mono-focal IOL (MoF),
were pooled for an analysis of 672 patients undergoing cataract
extraction. The TyPE questionnaire was administered at base-
line, and after both ﬁrst-eye and second-eye surgery. The TyPE
measures 67 items evaluating distance and near vision limita-
tions, social activities, glare and halo problems, and patient sat-
isfaction both with and without spectacles. Principal components
analyses (PCA) of the TyPE questionnaire were performed at
baseline, and after ﬁrst-eye and second-eye surgery. Factorial
coordinates were compared both between ReSTOR® and MoF
(t-tests), and between visits (paired t-tests). RESULTS: The ﬁrst
PCA factor (F1) concerned limitations to overall visual function.
The second factor (F2) concerned vision limitations without
spectacles. Overall, signiﬁcant improvements of visual function
were seen between baseline and ﬁrst-eye surgery (p < 0.0001),
and between ﬁrst-eye and second-eye surgery (p < 0.0001). At
baseline, no signiﬁcant differences were observed between treat-
ment groups with respect to F1 or F2. Vision after ﬁrst-eye
surgery was signiﬁcantly better in the ReSTOR® group than the
MoF group on both factors (F1: p < 0.006; F2: p < 0.001). These
differences between ReSTOR® and MoF were maintained and
reinforced after second-eye surgery (F1: p < 0.001; F2: p <
0.001). CONCLUSIONS: Mono-focal and ReSTOR® IOLs
both improved visual function, but only ReSTOR® improved the
“vision without spectacles” factor because, of course, the mono-
focal does not correct near vision.
PEY27
DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT
SATISFACTION WITH EYE DROPS IN OCULAR
HYPERTENSION AND GLAUCOMA
Berdeaux G1,Trudeau E2,Vigneux M2
1Alcon France, Rueil-Malmaison, France, 2Mapi Values, Lyon, France
OBJECTIVES: To describe the early development of a satisfac-
tion questionnaire for eye drops used in ocular hypertension and
glaucoma, developed in English and French simultaneously.
METHODS: A conceptual model of expectation and satisfaction
with eye drops was designed and used to guide patient (n = 15)
and clinician (n = 4) interviews in French and UK English. Fol-
lowing review of the interview responses, versions of the ques-
tionnaire were simultaneously developed in two languages and
then pilot-tested by six patients (three in France and three in 
the UK). RESULTS: After analysing the practitioners’ and the
patients’ interviews, six potential domains were identiﬁed as
having an impact on patients’ satisfaction regarding their eye
drop treatments. These domains are: 1) Patient characteristics
(16 items); 2) Treatment characteristics (4 items); 3) Relation-
ship between patient and practitioner (10 items); 4) Patients’ feel-
ings about their treatment (7 items); 5) Patients’ compliance (3
items); and 6) Interaction between the patient and the treatment
(six items). The questionnaire was developed using patients’ ver-
batim comments in each language. After a cognitive debrieﬁng
performed with six patients (six French and six English), the
wording and the domains of the questionnaire were conﬁrmed
in the two languages. CONCLUSION: The Eye Drops Satisfac-
tion Questionnaire (EDSQ) is now available in French and UK
English for use with patients receiving eye drops in ocular hyper-
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tension and glaucoma. Validation is currently underway to
examine the psychometric properties of the EDSQ questionnaire.
NEUROLOGICAL DISORDERSE
PND1
META-ANALYSIS OF THE EFFICACY AND TOLERABILITY OF
PRAMIPEXOLE AND ROPINIROLE IN RESTLESS LEGS
SYNDROME (RLS)
Quilici S1, Nicolas A2,Abrams K3, Martin M1, Lleu PL4, Finnern H5
1i3 Innovus, Uxbridge, Middlesex, UK, 2Centre Hospitalier le Vinatier,
Bron Cedex, France, 3University of Leicester, Leicester, UK,
4Boehringer Ingelheim France, Reims Cedex, France, 5Boehringer
Ingelheim GmbH, Ingelheim, Germany
OBJECTIVES: In the absence of comparative trials, to perform
a direct and indirect meta-analysis of the efﬁcacy and tolerabil-
ity of pramipexole (PPX) and ropinirole (RPR), both widely
approved treatments in RLS. METHODS: Clinical trials were
identiﬁed from a systematic search and clinical reports. Study
inclusion criteria: studies in idiopathic RLS, randomized, double-
blind, placebo-controlled, parallel group, primary endpoint:
International Restless Legs Rating Scale (IRLS). Pre-speciﬁed
analyses were: ﬁxed and random-effects models for direct com-
parisons and a Bayesian approach for the indirect comparison,
PPX vs. RPR, using placebo as the common comparator. Non-
inferiority of PPX vs. RPR was tested ﬁrst and then superiority.
Efﬁcacy criteria were: IRLS mean change from baseline and per-
centage of responders on the Clinical Global Impressions-
Improvement scale (CGI-I). Tolerability criteria were: incidence
of withdrawal and incidence of AEs occurring in >5% of
patients. RESULTS: Two trials were eligible for inclusion for
PPX (n = 689) and three for RPR (n = 931). The direct meta-
analysis, using random-effects model, conﬁrmed superior efﬁ-
cacy for both treatments vs. placebo measured as change on the
IRLS (PPX: −5.5; 95% CI: −7.7; −3.2; RPR: −3.2; 95% CI: −4.3;
−2.1) and for the CGI-I (PPX: OR = 3.0; 95% CI: 2.1; 4.3; RPR:
OR = 2.0; 95% CI: 1.5; 2.6). Compared to placebo the incidence
of nausea was signiﬁcantly higher for PPX (p < 0.01), whereas
dizziness, nausea, somnolence and vomiting were signiﬁcantly
higher for RPR (all p < 0.01). The Bayesian indirect comparison
showed a superior reduction on the IRLS for PPX vs. RPR of
”C2.3 points, and had an OR = 1.5 for the CGI-I responders.
The superior reduction on the IRLS, the higher CGI-I responder
rate and the reduced incidence of nausea and vomiting for PPX
vs. RPR were observed with a probability of ••97%. CON-
CLUSIONS: Results of the indirect meta-analysis were in favour
of PPX vs. RPR for IRLS and CGI-I and for the tolerability out-
comes nausea and vomiting.
PND2
ESTIMATING THE BUDGET IMPACT OF LEVETIRACETAM AS
ADJUNCTIVE THERAPY IN CHILDREN WITH REFRACTORY
PARTIAL ONSET SEIZURE IN THE UK
Heaney D1, Germe M2, Brown M3
1National Hospital for Neurology and Neurosurgery, London, UK,
2UCB, Braine-l’Alleud, Belgium, 3UCB, Slough, UK
OBJECTIVES: With about 33 million children affected world-
wide, epilepsy is a common neurological disorder creating sig-
niﬁcant socio-economic costs. This study aims to estimate the
additional costs or savings generated by the introduction of lev-
etiracetam for refractory partial onset seizure (POS) in paediatric
patients in the UK. METHODS: A budget impact model was
built from the UK NHS perspective, for a 5-year time period.
Levetiracetam adjunctive therapy was compared with standard
treatments (ST): lamotrigine, oxcarbazepine, valproic acid, car-
bamazepine and topiramate. Epidemiological paediatric popula-
tion data such as prevalence of refractory POS cases were
obtained from the published literature and combined with UK
population projections for 2005 from ofﬁcial statistics sources.
Patients on levetiracetam were divided into three groups: new,
existing and withdrawing patients to reﬂect the progressive
adoption of the treatment. The cost of medications and hospi-
talizations were included and expressed in 2005 UK£. RESULTS:
During the ﬁrst year, the number of paediatric patients with
refractory POS was estimated to be 7205. The annual cost per
patient for current ST was £1593, resulting in a total budget of
£11.5 million. Within the next ﬁve years, the number of paedi-
atric patients will increase to 7267, resulting in a total budget of
£11.6 million. Adding levetiracetam to ST increased the yearly
drug costs by £1089 per patient. This additional cost was partly
offset by lower hospitalization costs (£332 and £815 per patient
for levetiracetam and ST respectively). Introducing levetiracetam
resulted in a budget increase to £11.7 million (+1.8% compared
to current budget) during the ﬁrst year and £12.1 million
(+4.7%) over the next ﬁve years. CONCLUSION: Levetiracetam
as adjunctive therapy in paediatric patients with refractory POS
is predicted to result in a modest increase in UK NHS paediatric
epilepsy expenditure of 4.7% within a 5-year time period.
PND3
COST-EFFECTIVENESS ANALYSIS OF ADD-ON THERAPY IN
PARTIAL REFRACTORY EPILEPSY IN MEXICO
Constantino-Casas P1, Garcia-Contreras F1, Nevarez-Sida A1,
Del Angel-García G2, Rojas-Martínez E2, García-Constantino M2
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OBJECTIVE: To assess the cost-effectiveness of add-on therapy
drugs within the formulary of the Mexican Institute of Social
Security for partial refractory epilepsy. METHODS: Cost-
effectiveness study that used costs information from a retro-
spective cohort of a multicentric study. Efﬁcacy (>50% seizure
reduction) and adverse events of oxcarbazepine, topiramate, lev-
etiracetam and lamotrigine were obtained from a meta-analysis.
Experts suggested excluding vigabatrin from the analysis, and
gabapentin was also eliminated because IMSS formulary recom-
mends its use only for neuropathic pain. Study perspective was
institutional with 1 year time horizon, and no discount rate was
used. Costs were estimated from ﬁnancial information from
IMSS, and are reported in US 2006 dollars. A decision tree with
a Bayesian approach included efﬁcacy and adverse events. Mean
cost-effectiveness and incremental ratios, net health beneﬁts and
net economic beneﬁts were calculated. ICER conﬁdence interval
was estimated with ellipse method. Sensitivity analysis included
threshold, scenarios, one-way and probabilistic Monte Carlo
simulation. RESULTS: Levetiracetam had the lowest mean cost-
effectiveness ratio, $6238. Incremental analysis showed that top-
iramate was dominated by levetiracetam, while the ICER for
lamotrigine and oxcarbazepine was $1938 and $2156 compared
with not providing add-on therapy. Acceptability curves showed
that lamotrigine was the most cost-effective option with a WTP
between $955 and $1476. Levetiracetam was the most 
cost-effective option when WTP was above $1476, and the com-
ponents analysis conﬁrmed this result. CONCLUSIONS: Leve-
tiracetam was the alternative with lowest cost per controlled
patient and provided the largest health beneﬁt compared with
using standard therapy alone (not add-on). Topiramate was
dominated by levetiracetam. Standard therapy was the cheapest
alternative; however, due to its low effectiveness, it had more
